NCT04570839View on ClinicalTrials.gov

COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 31, 2020

Primary Completion Date

May 15, 2024

Study Completion Date

May 15, 2024

Conditions
Endometrial NeoplasmsOvarian CancerSolid TumorHead and Neck Cancer
Interventions
DRUG

COM701 in combination with BMS-986207 and nivolumab.

Study treatment with the 3 drug combination (COM701 in combination with BMS-986207 and nivolumab).

Trial Locations (9)

10032

Columbia University, New York

15232

University of Pittsburgh Cancer Center., Pittsburgh

21231

Johns Hopkins University Oncology Center., Baltimore

38138

The University of Tennessee WEST Cancer Center., Memphis

49503

START Midwest., Grand Rapids

60637

University of Chicago Medical Center, Chicago

77030

MD Anderson Cancer Center, Houston

78229

The START Center for Cancer Care., San Antonio

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

Compugen Ltd

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Compugen Ltd

INDUSTRY